Helmut Oettle, M.D., Ph.D., of the Charite - Universitatsmedizin Berlin, Germany, and colleagues conducted follow - up of a randomized trial that previously reported improvement in disease - free survival with
adjuvant (in addition to surgery)
gemcitabine therapy to determine if this treatment improved overall survival.
Inclusion Criteria: • The participant may have no more than 2 prior lines of systemic therapies (neoadjuvant and
adjuvant therapies will not be considered as a prior line of therapy) for advanced or metastatic disease and is suitable to receive
gemcitabine and docetaxel therapy.